Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Neuer Top-Geologe an Bord - zündet jetzt die nächste Kursrakete?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 1888 | ISIN: DEXXXXXXX122 | Ticker-Symbol: -
Branche
Pharma
Aktienmarkt
nicht börsennotiert
1-Jahres-Chart  (nicht börsennotiert)
BOEHRINGER INGELHEIM GMBH Chart 1 Jahr

Aktuelle News zur BOEHRINGER INGELHEIM

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTranspire follows in Boehringer's footsteps by licensing PDE4 inhibitor for lung disease1
28.05.Coreline Soft to Supply AI Lung Software to Boehringer Ingelheim8
27.05.Boehringer's nerandomilast shows lung function benefit in phase 3 IPF and PPF trials3
23.05.OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials at ASCO 2025213OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPa Blockade in Two Ongoing Trials...
► Artikel lesen
22.05.Boehringer Ingelheim Limited: Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPa blockade in two ongoing trials at ASCO 2025430· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals...
► Artikel lesen
BOEHRINGER INGELHEIM Aktie jetzt für 0€ handeln
22.05.The BioMed X Institute, Boehringer Ingelheim Launch Call for Research Proposals7
19.05.Boehringer Ingelheim Limited: Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo393Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER-IPF and FIBRONEER-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by...
► Artikel lesen
19.05.'Not game-changing': Boehringer's phase 3 lung data get muted response from analysts3
19.05.Boehringer Ingelheim erhält Marktzulassung für Blauzungen-Impfstoff in Deutschland311Ingelheim (ots) - - Der Impfstoff schützt Rinder und Schafe vor dem Blauzungenvirus Serotyp 3 (BTV-3) - Es ist der einzige BTV-3-Impfstoff, der laut Zulassung die klinischen Symptome der Erkrankung...
► Artikel lesen
16.05.Boehringer Ingelheim Taiwan Drives More Awareness for Proper Medicines Disposal356NORTHAMPTON, MA / ACCESS Newswire / May 16, 2025 / Picture this: You open your medicine cabinet and find a bottle of expired pills. What do you do? Toss them in the trash? Flush them down the toilet?We...
► Artikel lesen
16.05.Brainomix Presents Robust Validation of Its FDA-Cleared e-Lung Technology from its Collaboration with Boehringer Ingelheim388New studies presented at the American Thoracic Society (ATS) Conference this week validate e-Lung as an accurate tool to identify progressive pulmonary fibrosisOXFORD, England and CHICAGO...
► Artikel lesen
15.05.Boehringer partners Tempus AI to enhance cancer therapy pipeline13
14.05.Tempus partners with Boehringer Ingelheim to develop cancer treatments5
13.05.OMD baut Zusammenarbeit mit Boehringer Ingelheim weiter aus8
08.05.Boehringer advances oral therapy for geographic atrophy4
06.05.Boehringer Ingelheim Limited: Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy374Ingelheim, Germany, May 6, 2025 - Boehringer Ingelheim today announces the start of the JADE Phase II clinical study ([1] Geographic atrophy (GA) is an eye disease that can lead to irreversible vision...
► Artikel lesen
05.05.Boehringer Ingelheim Cares Foundation Expands Healthcare Access Across the United States of America253NORTHAMPTON, MA / ACCESS Newswire / May 5, 2025 / Boehringer IngelheimFacing challenges like job loss, isolation or addiction can push anyone to their limits. Carrie knows this first hand - after a...
► Artikel lesen
30.04.Boehringer, Oxford University and Cumulus to explore brain activity in BPD3
30.04.Carl Zeiss Meditec AG: ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care593Showcasing the future of ophthalmic research at ARVO 2025: ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating...
► Artikel lesen
29.04.Boehringer Ingelheim Limited: Breaking new ground in mental health research: Oxford University, Boehringer Ingelheim, and Cumulus Neuroscience launch first of its kind study investigating the day-to-day experience of patients with psychiatric disorders456Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025?- Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences...
► Artikel lesen
Seite:  Weiter >>
141 Nachrichten in den letzten 12 Monaten